Evidence required to demonstrate clinical utility of pharmacogenetic testing: the debate continues.
Pharmacogenetics is an area of research that has potential to greatly benefit patients. However, the routine use of diagnostic pharmacogenetic testing to inform treatment decisions is limited. Here we discuss the determination of clinical utility of pharmacogenetic testing and the level of evidence required to support translation into clinical practice.
Center for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.
N K
NK
Gillis
1] Center for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA [2] Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
F
F
Innocenti
D015415:Biomarkers; D005820:Genetic Testing; D006801:Humans; D010597:Pharmacogenetics; D017410:Practice Guidelines as Topic
D015415:Biomarkers